Daniel Weiss, M.D., Ph.D.

Room 226C, HSRF
University of Vermont, College of Medicine
149 Beaumont Ave.
Burlington, VT. 05405

Voice: (802) 656-8925
Fax: (802) 656-8926

Email: Daniel.Weiss@uvm.edu

• B.A. (1981) Biology; Cornell University, Ithaca, NY
• Ph.D. (1987) Pharmacology and Biomedical Science; City University of New York, New York, NY
• M.D. (1988) Mt. Sinai School of Medicine, New York, NY
• Intern in Internal Medicine (1989) University of Michigan Medical Center, Ann Arbor, MI
• Resident in Internal Medicine (1990-1991) University of Michigan Medical Center, Ann Arbor, MI
• Fellow in Pulmonary and Critical Care Disease (1992-1996) University of Washington School of Medicine, Seattle, WA
• Clinical Instructor in Medicine (1997-2001) University of Washington, Seattle, WA
• Staff Scientist (1997-2001) Fred Hutchinson Cancer Research Center, Seattle, WA
• Clinical Assistant Professor of Medicine (2001) University of Washington, Seattle, WA
• Assistant Professor of Medicine (2001-Present) University of Vermont College of Medicine, Burlington, VT
• Associate Director (2001-Present) Adult Cystic Fibrosis Clinic, Fletcher Allen Health Care, Burlington, VT

• Gene and Stem Cell Therapies for Lung Diseases
• Acute Lung Injury: Models, Mechanisms, and Therapeutic Approaches
• Cystic Fibrosis
• General Pulmonary and Critical Care Medicine

• Perflubron enhances adenovirus-mediated gene expression in lungs of transgenic mice with chronic alveolar filling.
   
   
• Perfluorochemical liquid enhances adeno-associated virus-mediated transgene expression in lungs.
   
   
• Use of perfluorochemical liquid allows earlier detection of gene expression and use of less vector in normal lung and enhances gene expression in acutely injured lung.
   
   
• Use of perflubron to enhance lung gene expression: safety and initial efficacy studies in non-human primates.